Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Hepatitis B vaccine in developing countries: problems and prospects.

E A Ayoola

    IARC Scientific Publications
    |January 1, 1984
    PubMed
    Summary
    This summary is machine-generated.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Hepatitis B and E viral infections among Nigerian healthcare workers.

    African journal of medicine and medical sciences·2013
    Same author

    Hepatic granulomas in an arab population: a retrospective study from a teaching hospital in Riyadh.

    Saudi journal of gastroenterology : official journal of the Saudi Gastroenterology Association·2009
    Same author

    Ulcerative colitis in Saudi Arabia: a retrospective analysis of 33 cases treated in a regional referral hospital in Gizan.

    Saudi journal of gastroenterology : official journal of the Saudi Gastroenterology Association·2009
    Same author

    The clinical pattern and complications of severe malaria in the Gizan region of Saudi Arabia.

    Annals of Saudi medicine·2007
    Same author

    Tumour markers and hepatitis C virus infection in Nigerian patients with liver diseases.

    Nigerian journal of medicine : journal of the National Association of Resident Doctors of Nigeria·2006
    Same author

    The clinical profile of cyclic vomiting syndrome in a regional hospital, Saudi Arabia.

    Tropical gastroenterology : official journal of the Digestive Diseases Foundation·2006
    Same journal

    North America.

    IARC scientific publications·2016
    Same journal

    Central and South America.

    IARC scientific publications·2016
    Same journal

    Africa.

    IARC scientific publications·2016
    Same journal

    Data availability and presentation.

    IARC scientific publications·2016
    Same journal

    Age standardization.

    IARC scientific publications·2016
    Same journal

    Data processing.

    IARC scientific publications·2016
    See all related articles

    Low-dose Hepatitis B vaccination using the intradermal route is effective in children, inducing significant anti-HBs antibody levels. Booster doses improved response in non-responders, with no adverse effects observed.

    Area of Science:

    • Immunology
    • Vaccinology
    • Public Health

    Background:

    • Hepatitis B vaccines are known for their high immunogenicity.
    • Evaluating low-dose and alternative administration routes is crucial for vaccine efficacy and accessibility.

    Purpose of the Study:

    • To assess the efficacy of low-dose Hepatitis B vaccination via subcutaneous and intradermal routes.
    • To investigate the impact of vaccination on chronic Hepatitis B surface antigen (HBsAg) carriers.
    • To evaluate booster vaccination responses in initial non-responders.

    Main Methods:

    • 197 Nigerian children received 3 monthly doses of Hevac B (2 micrograms), either subcutaneously (96) or intradermally (101).
    • 50 chronic HBsAg carriers were vaccinated, with outcomes compared to placebo.

    Related Experiment Videos

  • Booster vaccinations were administered to 50 initial non-responders.

    • Main Results:

    • Anti-HBs seropositivity was achieved in 82.3% (subcutaneous) and 74.3% (intradermal) of children post-vaccination.
    • No significant effect on HBsAg clearance or anti-HBs production was observed in chronic carriers.
    • Booster vaccination induced significant anti-HBs levels in 40% of initial non-responders, with no HBV infection development.

    Conclusions:

    • Low-dose Hepatitis B vaccination is effective, particularly via the intradermal route, which may be beneficial for developing countries.
    • The vaccine demonstrated a good safety profile with no adverse side-effects or immune complex formation.
    • Booster vaccination can elicit an immune response in a proportion of non-responders, contributing to Hepatitis B prevention strategies.